title: Advances in glucocorticoid-induced osteoporosis.
abstract: Glucocorticoid-induced osteoporosis (GIOP) is one of the most important side effects of glucocorticoid use, as it leads to an increased risk of fractures. Recently, many published studies have focused on the cellular and molecular mechanisms of bone metabolism, the pathophysiology of GIOP, and the intervention options to prevent GIOP. In this review, recent advances in GIOP are summarized, particularly recent progress in our understanding of the mechanisms of GIOP resulting in improved insight that might result in the development of new treatment options in the near future.
authors.affiliation: Department of Rheumatology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. d.denuyl@vumc.nl
authors.forename: Debby
authors.initials: D
authors.lastname: den Uyl
authors.forename: Irene E M
authors.initials: IE
authors.lastname: Bultink
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
mesh_terms: D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D005598:Fractures, Spontaneous / Q000139:chemically induced / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology* / Q000503:physiopathology; D012307:Risk Factors
chemical_list: D005938:Glucocorticoids